


This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended): Substituted pyrazoline compounds of formula I,



wherein

R<sup>1</sup> represents hydrogen or a linear or branched C<sub>1-4</sub>-alkyl group,

R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> independently of each other represent hydrogen, a linear or branched C<sub>1-6</sub>-alkyl group, a linear or branched C<sub>1-6</sub>-alkoxy group, a halogen atom, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CN, OH, NO<sub>2</sub>, -(C=O)-R<sup>8</sup>, SH, SR<sup>8</sup>, SOR<sup>8</sup>, SO<sub>2</sub>R<sup>8</sup>, NH<sub>2</sub>, NHR<sup>8</sup>, NR<sup>8</sup>R<sup>9</sup>, -(C=O)-NH<sub>2</sub>, -(C=O)-NHR<sup>8</sup> or -(C=O)-NR<sup>8</sup>R<sup>9</sup> whereby R<sup>8</sup> and R<sup>9</sup> for each substituent independently represent linear or branched C<sub>1-6</sub> alkyl,

R<sup>5</sup> and R<sup>6</sup> independently of each other represent a linear or branched C<sub>1-6</sub>-alkyl group, a linear or branched C<sub>1-6</sub>-alkoxy group, a halogen atom, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CN, OH, NO<sub>2</sub>, -(C=O)-R<sup>10</sup>, SH, SR<sup>10</sup>, SOR<sup>10</sup>, NH<sub>2</sub>, NHR<sup>10</sup>, NR<sup>10</sup>R<sup>11</sup>, -(C=O)-NH<sub>2</sub>, -(C=O)-NHR<sup>10</sup> or -(C=O)-NR<sup>10</sup>R<sup>11</sup>, whereby R<sup>10</sup> and optionally R<sup>11</sup> for each substituent independently represent linear or branched C<sub>1-6</sub> alkyl;

R<sup>7</sup> represents hydrogen, a linear or branched C<sub>1-6</sub>-alkyl group, a linear or branched C<sub>1-6</sub>-alkoxy group, a halogen atom, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CN, OH, NO<sub>2</sub>, -(C=O)-R<sup>10</sup>, SH, SR<sup>10</sup>, SOR<sup>10</sup>, NH<sub>2</sub>, NHR<sup>10</sup>, NR<sup>10</sup>R<sup>11</sup>, -(C=O)-NH<sub>2</sub>, -(C=O)-NHR<sup>10</sup> or -(C=O)-NR<sup>10</sup>R<sup>11</sup>, whereby R<sup>10</sup> and optionally

R<sup>11</sup> for each substituent independently represent linear or branched C<sub>1-6</sub> alkyl;

with the proviso that

if R<sup>1</sup> and R<sup>7</sup> are H and R<sup>5</sup> and R<sup>6</sup> both represent Cl in the 3- and 4-position of the phenyl ring neither of R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> may represent F in the 4-position of the phenyl ring if the other two of R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> both represent H;


optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof.

2. (original): Compounds according to claim 1, characterized in that at least one of R<sup>2</sup>, R<sup>3</sup> or R<sup>4</sup> represents hydrogen, while at least one of R<sup>2</sup>, R<sup>3</sup> or R<sup>4</sup> is different from hydrogen.
3. (previously presented): Compounds according to claim 1, characterized in that R<sup>7</sup> represents hydrogen.
4. (previously presented): Compounds according to claim 1, characterized in that R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> independently of each other represent hydrogen, a linear or branched C<sub>1-6</sub>-alkyl group, a halogen atom, or CF<sub>3</sub>.
5. (currently amended): Compounds according to claim 1, characterized in that R<sup>5</sup> and R<sup>6</sup> independently of each other represent a ~~linear or branched C<sub>1-6</sub>-alkyl group~~, a halogen atom, or CF<sub>3</sub>.
6. (previously presented): Compounds according to claim 1, characterized in that R<sup>2</sup> represents a chlorine atom in the 4-position of the phenyl ring, while R<sup>3</sup> and R<sup>4</sup> represent hydrogen.

7. (previously presented): Compounds according to claim 1, characterized in that R<sup>5</sup> and R<sup>6</sup> each represent chlorine atoms in the 2- and 4-position of the phenyl ring, while R<sup>7</sup> represents hydrogen.

8. (previously presented): Compounds according to claim 1, characterized in that R<sup>1</sup> represents hydrogen, methyl or ethyl.

9. (currently amended): Compounds of formula II according to claim 1



II

wherein

R<sup>1</sup> represents hydrogen or a linear or branched C<sub>1-4</sub>-alkyl group,

R<sup>12</sup> or R<sup>13</sup> independently of each other represent a linear or branched C<sub>1-6</sub>-alkyl group, a linear or branched C<sub>1-6</sub>-alkoxy group, a halogen atom, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CN, OH, NO<sub>2</sub>, SH, NH<sub>2</sub>, hydrogen, methyl, ethyl, F, Cl, Br or CF<sub>3</sub>,


R<sup>14</sup> or R<sup>15</sup> independently of each other represent a linear or branched C<sub>1-6</sub>-alkyl group, a linear or branched C<sub>1-6</sub>-alkoxy group, a halogen atom, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, CN, OH, NO<sub>2</sub>, SH, NH<sub>2</sub>, methyl, ethyl, F, Cl, Br or CF<sub>3</sub>,

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof.

10. (previously presented): Compounds according to claim 9 characterized in that R<sup>12</sup> and R<sup>13</sup> independently of each other represent hydrogen, a linear or branched C<sub>1-6</sub>-alkyl group, a halogen atom, or CF<sub>3</sub>.
11. (currently amended): Compounds according to claim 9, characterized in that R<sup>14</sup> and R<sup>15</sup> independently of each other represent a linear or branched C<sub>1-6</sub>-alkyl group, a halogen atom, or CF<sub>3</sub>.
12. (previously presented): Compounds according to claim 9, characterized in that R<sup>13</sup> represents Cl and R<sup>12</sup> represents hydrogen.
13. (previously presented): Compounds according to claim 9, characterized in that R<sup>14</sup> and R<sup>15</sup> each represent Cl.
14. (previously presented): Compounds according to claim 9, characterized in that R<sup>1</sup> represents hydrogen, methyl or ethyl.
15. (previously presented): A compound according to claim 1 which is:  
5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxylic acid,  
optionally in the form of a corresponding N-oxide, a corresponding salt.


Claim 16-39 (canceled)

40. (previously presented): Process for the manufacture of substituted pyrazoline compounds of formula I or II, wherein R<sup>1</sup> is hydrogen, according to claim 1, characterized in that at least one benzaldehyde compound of formula III




(III)

wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meaning according to claim 1, is reacted with a pyruvate compound of formula (IV)




(IV),

wherein G represents an OR group with R being a branched or unbranched C<sub>1-6</sub> alkyl radical or G represents an O<sup>-</sup>K group with K being a cation, to yield a compound of formula (V)




(V)

which is optionally isolated or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of formula (VI)



(VI)

or a corresponding salt thereof, wherein  $R^5$ ,  $R^6$  and  $R^7$  have the meaning according to claim 1, under inert atmosphere, to yield a compound of formula (VII)



(VII)

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> have the meaning as given above, which is optionally isolated or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of formula I according to claim 1 R<sup>1</sup> is a linear or branched C<sub>1-4</sub>-alkyl group.

41. (currently amended): Medicament Composition comprising at least one substituted pyrazoline compound of formula I or II according to claim 1, and optionally one or more pharmaceutically acceptable excipients.

Claims 42-86 (canceled)